Serum levels of antibodies and cross-reactive antibodies against the spike protein variants of SARS-CoV-2 in the vaccinated people and non-vaccinated people who have recovered from natural infection

Joint Webinar: 26^th World Congress on Advanced Biotechnology & 3^rd World Congress on Food Safety and Nutrition Science

April 27, 2023 | Webinar

Dablu Lal Gupta*, Subha Gupta, Jhasketan Meher, Anjan Giri, Eli Mohapatra, Manisha M Ruikar and DN Rao

All India Institute of Medical Sciences Raipur, India

ScientificTracks Abstracts: RRJMB

Abstract

The novel Corona Virus Disease 2019 (COVID-19) pandemic has severely affected people across the world. Currently, vaccination is the most effective method to prevent the spread of this disease. Despite the success of vaccination in greatly mitigating or eliminating the threat of diseases caused by SARS-CoV-2, the emerging new variants of this virus created a huge challenge in front of healthcare workers, society, and policymakers. In addition, vaccine development for people with compromised immunity and other pre-existing medical conditions has remained a major challenge. The spike protein of the SARS-CoV-2 is the major site of neutralizing antibodies and also shows robust mutation. Hence, it is crucial to understand the host immune response against spike protein variants of the virus. In the present study, we synthesized the peptides against the spike protein of wild type and variants of the SARS-CoV-2 virus to investigate the vaccine efficacy and humoral immune responses. The cross-reactivity of the antisera of vaccinated people and non-vaccinated people who have recovered from natural infections with these peptides helps us in determining the vaccine efficacy. Further, making the peptides against variants epitopes and testing the antibody titters in vaccinated people and non-vaccinated people who have recovered from natural infections give more insight into the humoral immune response against these variants. To this end, we performed a robust immunoinformatics approach based on multiple epitopes of the spike proteins of SARS-CoV-2. Key words: COVID-19, Vaccines, Antibodies, Immunoinformatics, SARS-CoV-2 variants

Biography

Dablu Lal Gupta is assistant professor at Department of Biochemistry, AIIMS, India. His research interest is analysis of innate and adaptive immune responses. He got DST Young Scientist award by Department of Science & Technology, Govt. of India in 2016, Dr. GP Talwar Young Scientist Award by Indian Immunology Society in 2016 and Young Research Scientist award by India-USA Emergency medicine forum in 2019.

• PDF
• HTML